Business Development

Sponsor TBA

Beyond Licensing- Models for Sharing Risk and Rewards

The session will evaluate recent deals that were structured to exploit technology and products in ways other than simple licensing. The panel, comprising key participants in these deals, will describe deal structures, advantages/disadvantages, and the legal and economic issues involved in choosing the structure, as well as how the structure is working in practice.

Chair: Jeffrey Wiesen, Chairman, Biotechnology Group, Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.

Speakers:

Anne Marie Cook, Assistant General Counsel, Biogen; Chris McLeod, Vice President, Curagen (invited); Jeffrey Wiesen, Chairman, Biotechnology Group, Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.; Creative Partnering Models for Pharmaceutical and Biotechnology Companies

Creative Partnering Models for Pharmaceutical and Biotechnology Companies

This session will include presentations from several pharmaceutical companies outlining creative partnering strategies they have implemented with biotechnology companies.

Chair: Dan Welch, President, Elan Pharmaceuticals

Growth Strategies and Business Models

This interactive session is designed to explore the merits of new and evolving growth strategies and business models. Panelists, representing a cross section of pharmaceutical and biotechnology interests, will present their views on key themes. The audience will then be invited to question panelists or offer alternative views regarding the impact of recent growth trends and strategies on business models.

Chair: Alan Williams, Chairman, Managing Resources Ltd.

Speakers: Peter Ringrose, CSO, Bristol-Myers Squibb Henri Termeer, President and CEO, Genzyme Corp. (invited) David Kent, Partner, Taylor Joynson Garrett Glyn Edwards, CEO, Antisoma plc Adrian Hobden, President, Myriad Pharmaceuticals

Doing Business with Nonbusiness Entities

Review strategic business-to-nonbusiness relationships including licensing agreements, technology transfer, spin-outs and venture capital funding with government agencies, nonprofit research institutes, charities and universities. Speakers will provide examples of successes and failures of these relationships and talk about the various roles nonbusinesses can fulfill.

Chair: Alice Lin, Vice Consul, Life Sciences and Health Care, British Consulate-General

Speakers:

Alison Campbell, Director, Intellectual Property, Medical Research Council Technology, UK; Alan Lamont, Business Development Manager, Catalyst BioMedica Ltd (Wellcome Trust); Al Collinson, Vice President, Business Development, Phylos, Inc.; Beatrice Leigh, Assistant Director, WW Academic Liaison, SmithKline Beecham

Scientific Due Diligence in Business Development-What Is It and Why Do I Care?

This session will examine the need for and the execution of scientific due diligence as it relates to M&A, product acquisitions or divestitures and venture capital investing. Experts from each of these fields will address the topics as follows:

1. Why does the science matter in M&A?

2. Scientific due diligence for product acquisitions.

3. Big pharma licensing - What we're looking for

4. Science and technology hurdles and how to overcome them for VCs

Chair: William McCulloch, M.D., Medical Director and Senior Vice President, A. M. Pappas & Associates, LLC

Clinical/Regulatory

Sponsored by Ernst & Young

Symposium on Clinical Results in an Advancing Regulatory Era: Maturing Xenotransplantation

Leaders in xenotransplantation will talk about the clinical and preclinical data in the ongoing xenotransplantation trials and plans for marketing applications for those products. This will also be an opportunity to share the outcome of several international initiatives taking place to address the con-duct of xenotransplantation trials, including efforts by the WHO/OECD on xenotransplantation surveillance, and an update on international policy and positions. Key regulators will discuss the evolving worldwide regulatory landscape, including the latest efforts in international harmonization and pharmacovigilance systems as the first xenotransplantation product marketing applications near completion.

Chair: E. Michael Egan, Senior Vice President, Diacrin, Inc.

Speakers: Andre La Praire, Health Canada; Dr. Amy Patterson, National Institute of Health (invited); Alison Lawton, Senior Vice President, Regulatory Affairs, Genzyme Corp.; Dr. F.X. Meslin, World Health Organization (invited); Dr. Julia Greenstein, Chief Scientific Officer, Biotransplant, Inc.

Bringing Genetic Medicine into the Mainstream

Serious barriers prevent biotechnology from identifying those at risk for transmitting or developing disease and offering medical options, including prevention. Three 20- minute presentations will bring participants up to date on 1) attempts to define analytic validity, clinical validity and clinical utility for testing of mutations in several model genes; 2) the steps needed to ensure that evolving technologies receive proper attention by the organizations that establish billing codes (e.g., CPT codes), fees and reimbursement; and 3) patenting, licensing and regulation of new technologies. The activities of the U.S. Department of Health and Human Services Secretary's Advisory Committee on Genetic Testing (SACGT) will also be reported.

Chair: Edward McCabe, M.D., Chair, Department of Pediatrics, UCLA, and Chair, SACGT, UCLA School of Medicine

Speakers:

Reed Pyeritz, M.D., Ph.D., Professor, University of Pittsburgh School of Medicine; Michelle Schoonmaker, Vice President, Corporate Development, Vysis, Inc.; Michael Watson, Ph.D., Executive Director, American College of Medical Genetics

Biotech and the Internet

Discussion by buyers, sellers and regulatory specialists of important regulatory and commercial issues raised by Internet transactions involving biotech compounds. Perspectives include: Food and Drug Administration (e.g., regulation of e-commerce sales, particularly pharmaceuticals, devices, off-label promotion); other regulatory agencies (biological products, genetically modified organisms, viruses and vectors); and commercial issues (e.g., title and transportation).

Chair: Kent Stormer, Partner, Heller Ehrman White & McAuliffe LLP

Speakers: Bruce Mackler, Partner, Heller Ehrman White & McAuliffe LLP; Nancy Cohen, General Counsel, Roche Bioscience; Cora Yang, General Counsel, Ventro

Developing AIDS Drugs for the New Millennium

Although the use of combination therapy has demonstrated significant therapeutic benefit, numerous challenges remain in patient treatment and clinical development of new drugs for HIV. Companies face the challenge of developing new strategies to navigate regulatory hurdles and successfully market their products with increasing competition. However, today's clinical landscape and shifting patient demographics present opportunities for companies to develop novel drugs that have attractive efficacy, safety, pharmacokinetic and/or resistance profiles.

Chair: David W. Barry, M.D., Chairman and CEO, Triangle Pharmaceuticals, Inc.

Getting the Right Cooks in the Kitchen: Forging Successful Clinical Alliances

Emerging biotechnology companies are especially under pres-sure to build clinical development programs that will produce meaningful results quickly, but they often lack the resources and infrastructure to support clinical studies entirely on their own. Therion Biologics, a company focused on developing therapeutic cancer vaccines, serves as a model for building a strong network of scientific, clinical and pharmaceutical collaborators that enable a growing company to quickly "ramp up" its clinical trials program. Representatives from govern-ment, industry, hospitals and the nonprofit sector discuss the unique assets and responsibilities that each party brings to the table when forging a successful clinical alliance.

Chair: Dennis Panicali, Ph.D., President and CEO, Therion Biologics Corp..4

Web-Based Acceleration of Clinical Development

Developers and users of Internet technologies will talk about how biotechnology companies can maximize their efficiency in drug development, clinical trial data collection and analysis using secure and private Web tools. For example, the Internet provides us with a ubiquitous network for connecting sponsors and investigator sites around the globe. Recruiting subjects as well as monitoring and managing of clinical trials has been expedited through Web-based management tools.

Chair: Steve George, Vice President, IT, PharmaNet

Speakers: Paul Bleicher, Chairman and CSO, Phase Forward; Rick Nelson, Senior Director, Clinical Operations Technologies, PharmaNet; David Heck, Senior Account Manager, CenterWatch

Improving Product Development Effectiveness on Finite Resources

Drugs entering the clinic have only a 5 percent chance of receiving permission to be marketed at the end of their development cycle, and many successful drugs do not get approved quickly. This important workshop will explore in detail how your company can maximize the chances for success. The members of the panel have all successfully developed products that have achieved great financial success.

Chair: Anthony Fox, M.D., Ph.D., FFPM, CBiol, FIBiol, President, EBD Group, Inc.

Speakers: David Shapiro, MB, ChB, MRCP, MFPM, President, Integrated Quality Resources

New European Regulations on Orphan Products: New Strategies for a Faster Access to the Market

This session will address the recently implemented European regulations for the development of therapeutic products intended to treat rare diseases. The regulations will be presented, with special emphasis on the advantages for drug developers, by the current head of the Orphan Medicinal Product department at the European Medicines Evaluation Agency (EMEA) and by the person who took the initiative for the European Directive on Orphan Medicinal Products. Industry representatives who have succeeded in obtaining orphan designation will present their experience, the positive and negative aspects, with a practical viewpoint.

Co-Chairs: Emmanuelle Voisin, Ph.D., Principal, Voisin Consultin; Brian Rudkin, Group Leader, Ecole Normale Superieure de Lyon

Speakers: Annie Wolff, Director, INSERM Patrick Lecourtois, Department Head, EMEA Robert Ibbotson, BSc, Regulatory Affairs Manager, Oxford GlycoSciences LTD

Communication

Sponsor TBA

Biotech in the Media - How Are We Doing?

The biotech industry has generated enormous press interest since the announcement of the Human Genome Project, the introduction of GMO crops and foods and the prescription drug debate, among others. How effectively has the industry presented itself and its case to the public on these issues from the media's perspective? How can the industry improve? A panel of reporters who cover our industry will discuss these questions.

Chair: Dan Eramian, Vice President, Communications, BIO

Launching A Blockbuster Product

Having spent many dollars, having made many promises the launching of a new drug must be executed with flare and military precision. This session will examine recent block-buster products and define the necessary IR/PR components from the perspectives of large and small companies - a new definition of what blockbuster programs will look like.

Chair: Theresa McCurry, Vice President, Hill and Knowlton

Speakers: Julia Levy, President and CEO, QLT, Inc;. John Langstaff, President and CEO, Cangene Corp.

Website.com - Guidelines for Product Disclosures in Light of FDA, SEC and FTC Regulation

Regulatory agencies, including the FDA, SEC and FTC have increased their monitoring of biotech company Web sites to look for violations of federal law. The FDA has issued warning letters, but biotech companies need to describe their products in development favorably to stimulate business partnerships and referrals for clinical trials. How can you mediate the conflicting needs of your Investor Relations, Marketing and Regulatory teams without provoking federal regulatory retaliation? The panel will cover the regulations, focus on case studies and their impact on biotech companies and address the impact of case law if any has developed by the end of June.

Chair: Linda Bentley, JD, Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.

Speakers:

Thomas Abrams, Director, FDA Division of Drug Marketing, Advertising and Communications (invited); William T. Whelan, JD, Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.; Marcia Kean, Managing Director, Feinstein Kean Healthcare

Sharing Public Opinion: A European Case Study

The Swiss Life-Sciences Industry, lead by large multination-als like Novartis, Roche, and Ares-Serono, has specific experience in shaping public opinion in favor of biotechnology. Two years ago, the Swiss biotechnology industry successfully fought a public vote to ban biotechnology research in Switzerland. By using new communication tools, Swiss Biotechnology helped to build public support for medically-oriented biotechnology research.

Chair: Mario Brossi, Chief Representative, Location: Switzerland

Speakers:

Juerg Randegger, Director, Novartis; Ernesto Bertarelli, CEO, Ares Serono; Roland Buehlmann, CEO and President, Swiss Association of Biotechnology Companies; Marc Friedli, Director, Swiss Federal Office of Health

Media Blitz: How to Turn Science into News

In this information-crowded age, it's often hard to get the public's attention on scientific topics. Using case studies, this session will discuss ways to make science news appealing, educational and powerful.

Chair: Tony Russo, CEO, Noonan/Russo Communications

Speakers: Renee Connolly, Assistant Vice President, Noonan/Russo Communications Rick Weiss, Science Reporter, Washington Post Robert Lanza, CEO, Advanced Cell Technology Schond Greenway, IR Director, Durect

Wired: E-Connecting with Your Patient Communities

The Internet has created the ability of patient communities, particularly those with physical disabilities, to have unprecedented access to information about research, care, treatment and support about their conditions. The panel will discuss trends regarding the increasing volume of patient traffic on the Web, the nature of the information demand and the essential ingredients of a company's successful Internet communications plan.

Chair: Tierney Saccavino, Manager of Communications, Acorda Therapeutics

Speakers:

Wise Young, M.D., Ph.D., Adviser, CanDo.Com; Kori Beer, Director of Communications, ViroPharma; Mary Fisher, Vice President, Marketing, Acorda Therapeutics

Converging Sciences

Sponsored by BioQ.com

Two symposia will be offered:

The Emergence of the Electronic FDA

This symposium will update attendees on the initiatives within the FDA to access regulatory information and auto-mate processes. Internet-based electronic and computerized submissions will be an emphasis of the symposium. Representatives from the FDA are anticipated. Industry case studies and practical approaches will be presented and discussed.

E-Solutions for the Life Science Industry

Key to the near-term future success of pharmaceutical and biotech industry will be the crafting of information technology strategies that encompass data mining, knowledge management, collaboration and process management. Technologies from the high-tech Internet economy are pro-viding solutions that affect all aspects of company operations, from R&D, through clinical studies and into commercial marketing.

New: e-Solutions for the Life Science Industry: Symposia

BIO 2001 is offering its participants a first: a focused analysis of how technology and the Internet are revolutionizing business processes in the life science industry. With the Internet and e-solutions part of many companies' strategies for success, conference organizers will offer valuable presentations by experts from companies such as IBM, Accenture and Sun Microsystems. These and other experts from hardware, software, integration and business process companies will provide detailed information on how to ride the wave of convergence occurring in the life science and technology sectors.

For the first time, biotechnology experts will learn about the types of problems e-solutions can solve, the definitions of technology solutions, and how recent advancements in technology translate into productivity gains across an enterprise. BIO 2001 attendees can expect to hear from experts in the areas of knowledge management, information management, e-training and Internet-based electronic product submissions.

Doing Business Globally

Sponsor TBA

Collaborating with Universities Around the Globe - Business Opportunities for U.S. Biotech Companies

Outside the USA, much of the world's promising biotech research is conducted in publicly funded universities. Many of these are increasingly receptive to private-sector collaborations, thus creating exciting new opportunities for biotech companies seeking to enhance their technology portfolios. Drawing on the experiences of university representatives and advisers from a number of different countries, this session aims to provide practical guidance on achieving successful deals with such overseas universities.

Chair: Mark Hawes, Partner, Bristows

Speakers:

Cengiz Tarhan, Director of Commercial & Medical School Accounting, University College London; Ceasar Anquillare, President and Chief Executive, Winchester Capital; Dr. Mitsutaka Iwasaki, Patent Attorney, Aoyama & Partners, Japan Laura Anderson, Intellectual Property Law Partner, Bristows

Canadian Biotech-Thinking

This session will present the views of leaders of Biotech in Canada and will provide some insight into the environment and management character in the Biotech world in Canada. This segment will be an excellent preview of Canadian Biotech.

Chair: Alex McPherson, President and CEO, Biomira, Inc.

Speakers:

Julia Levy, President and CEO, QLT Inc.; Francesco Bellini, Chairman, Biochem Pharma (invited); Mark Lievonen, President and CEO, Aventis

Japan: Strategic Partnering Realities in 2001

Japan's major drug companies and regulatory and economic environment are not what you saw only a few years ago. Four well-known Japanese pharmaceutical industry insiders share their year of intimate Japan experiences and expertise. Their in-depth, up-to-date presentations will provide you with realistic, practical 2001+ key input and answers for your Japan strategic planning.

Chair: Ted Tanaka, President, Tanaka International, Inc.

Speakers:

Ted Tanaka, President, Tanaka International, Inc. Kazuo Nakamura, President, CMIC Co., Ltd. Masanori Fukushima, Professor, University of Kyoto Philip N. Sussman, Executive Vice President, Corporate Development, Memory Pharmaceuticals Corp.

Food and Agriculture

Sponsor TBA

Safety and Regulatory Oversight of Novel Crops Symposium: A Public Discussion

U.S. government representatives will present their views on the comprehensive nature of their oversight, communication with the public, and mechanisms for public input to their decision-making. Representatives from public interest groups will present their views on current and emerging issues. A panel discussion will follow.

Golden Rice: Public/Private Cooperation to Battle Malnutrition

Golden Rice has emerged as a clear example of how biotechnology can address food problems previously unapproachable through traditional plant breeding. Speakers will review how public and private sector cooperation created this advance for malnourished populations, and lessons learned for future improvements to the world's food supply.

Improving the Safety of Existing Foods Through Biotechnology

Although little-known, virtually all foods contain natural allergens, carcinogens, mutagens, toxins and anti-nutritional factors. Conventional breeding has made gradual progress in reducing some of these undesired components. Specific examples of using biotechnology to further enhance the safety of existing foods will be reviewed.

Spare the Plow: Environmental Benefits of Biotechnology

Specific studies will be presented documenting the beneficial environmental effects of biotechnology on agricultural sustainability, biodiversity, fossil fuel use, soil compaction and erosion, water quality, and reduced pressure to convert wilderness lands to agriculture.

Accepting New Technology: Media and Public Perception of Risks and Benefits

Speakers will talk about how new technology is viewed by the public and the media. They will also give guidance on how to accurately communicate new technology to the public.

Lack of Global Harmonization and Challenges for Developing Countries

Biotechnology promises more benefit to developing nations than other technologies such as mechanization, agricultural chemicals, and hybridization. This is because biotechnology demands less capital investment, less sophisticated infra-structure, and is less scale-dependent. These benefits, how-ever, will be diminished, if not eliminated, by conflicting worldwide regulations that threaten to impose high cost infrastructures such as identity preservation and unrealistic labeling requirements. Speakers will address the impact of these potential requirements for developing countries.

The Global Trade Dilemma A mishmash of conflicting and increasingly expensive regulations impedes international trade, largely between developed countries. Without resolution, this problem could eventually encompass all importing and exporting nations-an international Tower of Babel in the making. Speakers will review the current impacts on trade, including costs and barriers.

Agricultural Biotechnology: From Farm to Pharm The first biotechnology modifications to crops focused on traditional agriculture production such as yield, quality and crop protection. The second wave of applications will concentrate on advances such as using green plants instead of steel plants to produce chemical compounds, plastics and pharmaceuticals.

Finance

Sponsor TBA

The Finance track is historically one of the most popular tracks of the BIO 2001 International Convention. We plan to have eighteen hours of up-to-date, timely and relevant programming featuring the best speakers and experts in their fields. The range of topics to be covered at BIO 2001 include: Sell-Side Analysts: A 2001 Roundup; Creative Strategies: From Start-up to IPO; The Latest in Debt Financing Alternatives; Current M&A Trends and Deal Structures; Spinoffs and Joint Ventures as Financing Tools; Venture Capital Opportunities on a Global Front.

Industrial and Environmental

Sponsored by San Diego Port Authority

The Industrial and Environmental Section Program for BIO 2001 emphasizes the role industrial and environmental biotechnology will play in helping achieve industrial and environmental sustainability. As the world population grows, new technologies are needed to reduce the impact of industrial activity and manufacturing on the our natural environ-ment. The development of new biobased products, biocatalysts and green chemistry will revolutionize manufacturing activities over the next decade, opening the way to continued economic development and a cleaner environment.

Monday: Sessions on Industrial and Environmental Sustainability

Tuesday: Sessions on New Biocatalyst Technologies

Wednesday: Sessions on Enzymatic Biomass Conversion to Produce Energy and Reduce Greenhouse Emissions

Intellectual Property/Legal

Sponsored by Brobeck, Phleger & Harrison, LLP CLE certificates will be administered by Biolawbusiness.com (The Journal of BioLaw & Business.)

Be an Intellectual Capitalist: Creating Value from Your Intellectual Property

This presentation will help biotech executives become intellectual capitalists. We will demonstrate how the tools of a disciplined financial market can help them create value from their intangible assets. This discussion will provide participants with real solutions for obtaining value from their intellectual property.

Chair: Nir Kossovsky, CEO, The Patent & License Exchange

Speakers:

Alex Arrow, CFO, The Patent & License Exchange; Bruce Lehman, Former Commissioner, U.S. Patent and Trademark Office

Building and Maintaining a Winning Patent Portfolio: Strategic Considerations

For biotechnology companies the key to commercial success and corporate survival relies heavily on the strength of the patent portfolio. The speakers will address various issues and strategies that a successful company should consider in developing, maintaining and positioning a strong patent portfolio.

Chair: John Wetherell, Principal, Fish & Richardson PC

Speakers: John Doll, Group Director Biotech, USPTO; Gregory Einhorn, Associate, Fish & Richardson PC

Creating and Managing Pharmaceutical Patent Portfolios

The panel will address the challenge of creating and managing pharmaceutical patent portfolios from the perspective of both the large pharmaceutical company and the start-up initiative. Topics that the speakers will address will include when to file patent applications, how broadly to file, defensive and offensive filing strategies, where to file outside the United States, working with international counsel and managing interparties proceedings both in the United States and in foreign countries.

Chair: Sherry M. Knowles, Esq., Partner, King & Spalding

Speakers:

Blair Q. Ferguson, Esq., Vice President, Chief Patent and Trademark Counsel, DuPont Pharmaceuticals, Inc.; Jean-Pierre Sommadossi, Ph.D., President and CEO, Novirio Pharmaceuticals, Inc;. Raymond F. Schinazi, Ph.D., Director, Pharmasset, Inc.

Partnering for Life . . .Partnering for Health

Patent Disclosure vs. Scope of Claim: The Courts' Views - U.S., Europe and Japan The session will address one of the major issues in biotech patent law today: How much disclosure is required in a patent to permit enforcement of a broad patent claim? The goal of the session is to address the relevant decisions and trends in patent enforcement in the United States, Europe and Japan on this balance of disclosure and scope of claim in biotech patents. The session will be of interest to lawyers, business executives and analysts alike.

Chair: James F. Haley Jr., Partner, Fish & Neave

The Business-IP Interface in Bioinformatics

Functional genomics and bioinformatics increasingly pervade biotechnology as biology transforms from a one-dimensional science concerned with single genes to a multi-dimensional one focused on such endeavors as gigabase sequence annotation and deciphering the myriad functional interactions among thousands of genes monitored simultaneously. With this transformation comes a commensurate shift in the business models and underlying IP strategies driving the new biology to market. This presentation will convey approaches and perspectives of two emerging bioinformatics leaders and a major bioinformatics consumer, with insights from respective experts on essential valuation, enforcement and policy issues that define the bioinformatics business-IP landscape.

Chair: Arie Michelsohn, Associate, Finnegan, Henderson, Farabow, Garrett & Dunner

Speakers:

Mark Boguski, Vice President, Rosetta Inpharmatics; Caroline Kovac, Vice President, Life Science Solutions, IBM; Steve Kunin, Deputy Commissioner for Patent Examination Policy, U.S. Patent and Trademark Office (invited); Charles Lipsey, Partner, Finnegan, Henderson, Farabow, Garrett & Dunner; Richard Razgaitis, Principal, InteCap, Inc.; Thomas Webster, Corporate Patent Counsel, Eli Lilly & Co.

The Great Patent Debate: The Role of IP in Biotherapeutics

Between visible debates in the courtroom involving biotech's leading companies and recent public discussion of gene patents, biotech IP seems to be on everyone's mind. Hear from top genomics companies, U.S. patent officers and patent lawyers how securing gene patents continues to be a fundamental issue for any developer of biotherapeutic drugs. The speakers will address effective IP strategies, building business opportunities around biotech patent port-folios and, of course, the public debate over gene patenting.

Chair: Bruce Carter, Ph.D., President and CEO, ZymoGenetics, Inc.

Speakers:

George Rathmann, Ph.D., President and CEO, Hyseq, Inc.; William Haseltine, Ph.D., President and Chairman, Human Genome Sciences; Lars Rebien Sorensen, Executive Vice President, Health Care Group, Novo Nordisk A/S; Steven Singer, Vice President, Life Sciences Group, Hale & Dorr, LLP

Policy and Ethics

Sponsor TBA

As the United States regains its balance from one of the closest elections in U.S. history, the Congress and many state legislatures will have to struggle with a host of complicated issues with potential implications for the biotechnology industry. The Government Relations Policy Track at BIO 2001 will focus on many of the important issues being debated in federal and state legislatures today. These issues include providing prescription drug benefits to the elderly and low income families, bioethics issues including human stem cell research, gene therapy, protecting human subjects in research, genetic discrimination, the reauthorization of the Prescription Drug User Fee Act (PDUFA) and possible revisions to the Food and Drug Administration Modernization Act (FDAMA), and intellectual property issues including a possible discussion of gene patenting and changes to the Hatch-Waxman Act.

Product Development/ Manufacturing

Sponsored by DSM Biologics Enhancing the Value of Biotechnology Products: Formulation and Drug Delivery Strategies

Enhanced formulations and advanced drug delivery systems can provide "enabling technology" and greatly increase the patient acceptance, convenience and compliance with biotechnology drugs. Speakers will cover partnering strategies and provide examples of successful drug delivery technologies that have been applied to biotechnology products.

Chair: Mary L. Martin, Ph.D., Vice President, Biotechnology Research, Elan Pharmaceutical Technologies

Speakers:

Larry Sternson, President, Elan Pharmaceuticals Technologies

Clinical and Preclinical Progress on Transgenically Sourced Biopharmaceuticals

Presentations will be made by three companies that currently have in human clinical trials products that have been produced in the milk of transgenic animals. A status report will be given on the clinical progress of each of these products. Products actively in development by these companies will also be discussed.

Chair: Michael Young, Vice President, Commercial Development, Genzyme Transgenics Corp.

Speakers:

Alan Colman, Ph.D., Vice President, Research, PPL Therapeutics, Inc. Frank Pieper, Ph.D., Vice President, Pharming BV Timothy Maines, Director of Quality, Genzyme Transgenics Corp.

Glycosylation in the Era of Proteomics: Will Sugars Be the Limiting Factor in Protein Production?

Glycoproteins secreted by recombinant cell expression systems or transgenic organisms frequently contain sugar chains that lack sugar units present in the native molecule and may contain sugars or linkage units never expressed by human cells. Many new protein expression systems are being developed to keep pace with the rapidly expanding set of new protein drug opportunities created by the genomic and proteomic revolution. This session will include descriptions of factors that affect glycoform expression in commonly used CHO cell systems, patterns of carbohydrates characteristic of nonmammalian recombinant and transgenic systems, and a novel method for in vitro enzymatic remodeling of carbohydrate chains using glycosyltransferases.

Chair: David Zopf, Vice President, Drug Development, Neose Technologies, Inc.

A Worldwide Shortage of Biomanufacturing Capacity for Monoclonal Antibodies

Humanized monoclonal antibodies (Hu-MAbs) play an important role in medicine by providing a safe and effective class of therapeutics indicated for many chronic unmet medical needs. Although exquisitely specific, Hu-MAbs generally are administered in large doses requiring hundreds of kilograms of recombinant product to be biomanufactured each year. This presentation looks at the dynamics of the Hu-MAb market, current global biomanufacturing capacities and new technologies for producing these products; it also provides scenarios for meeting future biomanufacturing needs for Hu-Mabs.

Chair: Bryan Lawlis, Chairman, Covance Biotechnology Services

Speakers:

Parrish Galliher, Vice President, Manufacturing, Millennium Pharmaceuticals, Inc.; Rob Arathoon, Vice President, Manufacturing and Process Sciences, Genentech; John Howard, CEO, Prodigene; Barry White, General Manager, Integrated Plant Technologies

Outsourcing and Seamless Integration - A New Paradigm for Pharmaceutical Development

The need to fulfill growth expectations in pharmaceutical development has generated a drive to boost throughput and cut time-to-market for new products. Various approaches have been adopted by pharmaceutical and biopharmaceutical companies based on both limited outsourcing strategies and more creative approaches, and this seminar will discuss these. However, more needs to be done, and the seamless integration of development services through outsourcing offers a new paradigm for pharmaceutical development with market skills allied to service and novel technologies promoting high-quality, faster development of new therapeutics.

Co-Chairs: Anthony Barrett, Department of Chemistry, Imperial College Of Science, Technology and Medicine; Ed Robinson, Vice President, General Manager, Solutia Pharmaceutical Services

Speakers:

Jim Nash, Vice President, Manufacturing, Millennium Pharmaceuticals, Inc.; Archie Campbell, Vice President, Biologic Process Research, Pharmacia Corp.; John Fromson, CSO, DevCo Pharmaceuticals

Plants as Production Vehicles for Therapeutic Proteins

Plants and plant cells have become increasingly popular as a vehicle for the production of therapeutic proteins and pep-tides. The speakers in this session will describe the most recent advances in the use of plants as production hosts for therapeutic proteins. This presentation will cover the use of a wide variety of products produced in different crops using different production systems.

Chair: Gijs van Rooijen, Head, Cellular and Molecular Biology, SemBioSys Genetics, Inc.

Speakers:

Elizabeth Hood, Vice President, Technology, Prodigene; Jon MacIntyre, Monsanto Company, Integrated Protein Technologies; Klaus Düring, President and CEO, MPB Cologne GmbH; Gijs van Rooijen, Head, Cellular and Molecular Biology, SemBioSys Genetics, Inc.

Sales/Marketing

Sponsor TBA

Emerging Drug Discovery Tools Companies and Commercialization Models for Value Creation

Symposium

A bioStrategies Group analysis of business models and value creation in the Drug Discovery Tools Companies segment will be presented. Then selected leading companies representing a variety of the tools discovery sectors including genomics, proteomics, expression analysis and bioinformatics will present commercialization models, busi-ness strategies and analysis of the market dynamics and drivers for their respective sectors.

Chair: Gary Sams, Principal, bioStrategies Group

E-Business Initiatives - Current Options and Future Prospects

The session will discuss e-business initiatives relating to pharmaceutical sales and marketing environments. It will focus on methods, for example "e-detailing," that offer pharma and biotech solutions to sales and marketing issues.

Chair: Robert Keith, Vice President, Commercial Strategy and Marketing, Dura Pharmaceuticals, Inc.

Speakers:

Robert Keith, Vice President, Commercial Strategy and Marketing, Dura Pharmaceuticals, Inc.; Michael Grey, President and CEO, Trega Biosciences, Inc.

How Will the Biotechnology Revolution Affect the Current U.S. Health-Care Supply System?

For the first time, an analysis has been completed on how all biotechnology compounds in development may affect the current market - what their impact is on today's therapies, delivery systems, treatment sites and payment systems. Implications for key health-care stakeholders will be presented. The study findings represent an important set of issues that will need to be addressed before the benefits of new biotechnology pharmaceuticals will be realized.

Chair: Marsha Millonig, Vice President, Research and Information, National Wholesale Druggists' Association

Is Your Molecule Ready to Market? - Incorporating Marketing Objectives into Clinical Development

Historically, the biotech industry and much of pharma focused solely on the NDA - not on enhancing the value of the approved product when planning clinical trial design. This myopia often resulted in unnecessary marketing limitations due to an unnecessarily restrictive label. Each panelist will discuss new strategies for ensuring that your product will be able to reach its full potential after FDA approval. The discussion will key off of case studies that focus on early-stage molecules.

Chair: Mark King, Managing Director, Feinstein Kean Healthcare - Kendall Strategies

Speakers:

Tom Joyce, Director Antivirals, Agouron Pharmaceuticals; Kathryn Jones, Senior Director, Market Research, Wyeth-Ayerst Global Pharmaceuticals; Alain Goulet, Director of Marketing, Biochem Pharma

Outreach: Building the Ties with Patient Advocates for Long-Term Success

Company success is ultimately achieved through product acceptance, and outreach to the consumers and their advocates early in the process can build the relationships that lead to this success. This session will include specific examples on working with patient organizations to gain rapid acceptance/use of new products; case studies on working with patient organizations to develop accelerated enroll-ment of patients in clinical trials; discussion on best practices in working with patient groups; and CEO presentations on outreach to support broader corporate goals and building shareholder value through outreach. Presentations will also include patient advocates and others from the patient community who can influence company success.

Chair: Michael Losow, Outreach Director, BIO

Speakers:

Michael Young, Vice President, Ligand Pharmaceuticals Ernesto Bertarelli, Chairman/CEO, Ares Serono (invited) Blair Underwood, Volunteer/Actor, ALS Association

Effective Pricing-Maximizing the Potential of Biotechnology

Even though pricing plays a critical role in the success or failure of biotechnology companies through its direct impact on sales, revenues and profits, biotech companies usually focus more on the capabilities of their products and less on fully exploiting market potential. In this session, we will look at the role of pricing at all stages of the product life-cycle in maximizing the success of biotech companies. Speakers from biotechnology, pharmaceutical and consulting companies will share their knowledge and demonstrate state-of-the-art approaches to effective pricing.

Chair: Klaus Hilleke, Senior Partner, Simon-Kucher & Partners

Speakers:

Boris Simkovich, Partner, Simon-Kucher & Partners Bill Aliski, Vice President, Health Services, Transkaryotic Therapies David Wierz, Senior Director Global Strategic Marketing, Wyeth-Ayerst

From Indication to Franchise

Biopharmaceutical companies often face the challenge and opportunity to expand from an initial indication to multi-ple, potentially disparate markets for their products. In doing so, they face strategic challenges in pricing and positioning the product across different audiences with different needs and expectations, and they face organizational challenges in developing core competencies that build from a product/indication focus into a franchise. The panel will draw on experiences at Allergan and other companies to offer a strategic framework as well as practical advice in addressing these challenges.

Chair: Alexander Johns, President, bioStrategies Group

Speakers:

Greg Brooks, Vice President, Global Marketing, Allergan Robert Bancroft, Director, Global Marketing, Allergan Monica Alfaro-Welling, Director, U.S. Marketing, Allergan David Perkins, Team Leader, Endocrinology Products, Genentech

The BIO 2001 Exhibit Hall

A spectacular viewing of the best biotechnology has to offer. Come out and network with over 750 exhibitors represent-ing more than 15 countries and 40 states. Representatives from laboratories, pharmaceutical companies, state economic and development agencies, print publications, law firms and supply companies will be on hand to display and present the latest techniques and devices used in our industry.

The BIO 2001 Exhibit Hall will feature:

• The largest exhibition in the history of this event - More than 156,000 gross square feet

• An Exhibit Hall Networking Reception, Tuesday Evening, 4:30 PM - 6:30 PM Exhibit Hall reception is sponsored by: Stroock & Stroock & Lavan LLP and Wallonia Region of Belguim

• International and domestic pavilions with companies from specific regions displaying their expertise

• A convenient internet café including a searchable BIO 2001 exhibitor database to make finding the company or type of company you need quickly The BIO 2001 Exhibit Hall will be open Monday June 25 -Wednesday, June 27, 2001 from 9:30 AM to 4:30 PM (Tuesday hours will be extended to 6:30 to include the Exhibit Hall Networking Reception).

Save the Date ... Sunday, June 24 Tee Off Against ALS

This is your chance to play golf at one of San Diego's most prestigious golf courses.

All proceeds will benefit the ALS Association, the only national nonprofit organization dedicated solely to the fight against ALS (Lou Gehrig's disease). Space is very limited for this event, so look for your registration materials and sign up early!

BIO 2001 Convention - Daily Schedule at a Glance

7:00 - 8:00 a.m. Plenary Breakfast with Keynote Speakers

8:15 - 11:45 a.m Morning Symposia & Sessions

9:30 a.m. - 4:30 p.m. Exhibit Hall Open

12:00 - 1:45 p.m. Luncheon with Keynote Speakers

2:00 - 5:30 p.m. Afternoon Symposia & Sessions.

Science

Sponsored by Merck & Co. and TBA Animal, Mineral or Vegetable: Which Model for Product Discovery?

At the birth of the genomics industry, new companies were formed, each with its own innovative method for discovering gene function. It is the usefulness and productivity of these tools, however, that truly lead to the companies' success. This panel provides the opportunity for a lively discussion about the utility of different gene-based discovery models; each model has uniquely influenced the success of the genomics industry and has drawn significant attention from the investment community. These developments reflect the growing demand of the genomics industry.

Speakers:

John Ryals, CEO, Paradigm Genetics; Arthur Sands, M.D., Ph.D., CEO, Lexicon Genetics, Inc. (invited)

Innovations in Inflammation: Novel Approaches in the Treatment and Management of Inflammation

This presentation will highlight a number of different and innovative approaches to the management and treatment of chronic inflammatory disease, which include asthma, rheumatoid arthritis, psoriasis and inflammatory bowel dis-ease and afflict millions of people, causing untold suffering and significant costs to health-care systems worldwide. Traditional approaches in the treatment and management of inflammatory disease are often palliative, having little or no affect on the underlying disease process and are often limited by severe side effects. These markets represent an area of significant unmet medical need.

Chair: David Molowa, Ph.D., Senior Analyst, Health Care and Biotechnology, Chase H&Q

Speakers:

Barbara Finck, M.D., Medical Director, Clinical Development, Immunex Corp.; Kevin Mullane, Ph.D., Senior Vice President, Research and Development, Inflazyme Pharmaceuticals Ltd.; Barrie Carter, Ph.D., Executive Vice President and Director, Research and Development, Targeted Genetics Corp.

Innovative Cancer Therapies

Biotech is on the brink of bringing diverse and innovative therapies to the market for the treatment of cancer. Approaches vary, but the goal is united - to bring safe, cost-effective products to the bedside of patients. These product candidates may drastically alter the treatment and manage-ment of cancer.

Chair: Alex McPherson, M.D., Ph.D., President and CEO, Biomira, Inc.

Speakers:

Alex McPherson, M.D., Ph.D., President and CEO, Biomira, Inc.; Garo Arman, Ph.D, CEO, Antigenics; Samuel Waksal, President and CEO, ImClone Systems, Inc.; Paul Abrams, M.D., JD, CEO, NeoRx; John Holaday, Ph.D., Chairman and CEO, EntreMed

Methods for Phenotypic Evaluation of Transgenic and Knockout Mice

Technological advancements enabling investigators to genetically engineer mice quickly and efficiently have created a deluge of models available for research today. Unfortunately, not all mice are created equal. The trend toward comprehensive genotyping/phenotyping programs at the outset of drug-discovery efforts aid in the selection of the best study models, ultimately saving valuable research time and money in bringing therapeutics to market.

Chair: Jacqueline Crawley, Ph.D., National Institute of Mental Health

Speakers:

Jacqueline Crawley, Ph.D., National Institute of Mental Health; Kathleen Murray, DVM, MS, Charles River Laboratories; Carolyn Moyer, DVM, Pathology Associates International; Bruce Elder, Ph.D., Charles River Laboratories

Optimizing Genes and Proteins with Directed Evolution Technologies

This panel will include members of the major companies in the burgeoning field of directed evolution discussing the technology, applications and case studies of their technologies in fields such as human therapeutics, agriculture and industrial enzymes. The panel will be of interest to pharmaceutical business development executives, representatives of agricultural and biotechnology companies in all capacities and financial community members. The overarching theme will be the ability to customize novel and improve existing compounds "to order."

Chair: Andy Ellington, Ph.D., Professor, University of Texas

Speakers:

William Huse, M.D., Ph.D., CEO, Applied Molecular Evolution

Postgenomics: Making Sense of DNA's Secrets

While completion of the first draft of the human genome has been hailed as a historic achievement, the genome sequence actually represents a new starting point for science and medicine. A multifaceted effort is already under way to functionally analyze the human genome to understand the genes involved in inherited traits, differentiation and disease. This session will focus on important postgenomic technologies that provide solutions for developing better therapies, diagnostics and biomedical products through approaches such as gene regulation, functional genomics, pharmacogenomics and proteomics.

Chair: Mary Harper, CSO, CIStem Molecular Corp..

Speakers:

Charles Cantor, CSO, Sequenom, Inc.; Willem Stemmer, Vice President, Research, Maxygen, Inc.; Mary Harper, CSO, CIStem Molecular Corp.; David Mack, Vice President, Genomics Research, Eos Biotechnology, Inc.

Research Begets Biotech: The San Diego Story

This panel discussion will explain the genesis and rapid development of the San Diego biotech industry. The concen-tration of world-class research and educational institutions in San Diego sparked the development of one of the three largest and fastest growing centers of biotech innovation in the world. Learn how a variety of nonprofit organizations have collaborated with industry to advance basic technology.

Chair: Joe Panetta, President and CEO, BIOCOM/san diego

Speakers:

Cheryl Moore, Vice President and Chief Administrative Officer, The Burnham Institute; Fred Cutler, Director, UCSD CONNECT; Stanley Kim, Patent Counsel, The Salk Institute; Alan Paau, Director, Tech Transfer and IP Services, UCSD; Stuart Gordon, Director, Technology Transfer, San Diego State University

The Return of Monoclonal Antibodies in the Fight Against Cancer and Infectious Diseases

This session will deal with the birth, death and rebirth of this novel disease-fighting tool...monoclonal antibodies. It will address the growth of the fully human monoclonal anti-body business and how it is shaping new treatments in the areas of oncology and infectious disease.

Chair: Dr. Martin Becker, CEO, XTL Biopharmaceuticals

Speakers:

Michael Hanna, Ph.D., President and CEO, CSO, Intracel Corporation; Louis Weiner, M.C., Chairman, Medical Oncology, Fox Chase Cancer Center; Donald Drakeman, J.D., Ph.D., President and CEO, Medarex

TNF Blockers: The Next Billion-Dollar Market

The recent clinical and commercial success of the anti-TNF therapies Enbrel and Inflixinab has created tremendous interest in exploring these protein drugs for many diseases involving inflammatory processes, including autoimmune diseases and congestive heart failure. One approach to creating cheaper, patient-friendly, small-molecule drugs that block TNF production involves modifying thalidomide. This symposium is intended to offer an overview of the current and future approaches to blocking TNF and to outline their very exciting clinical and commercial potential.

Chair: Caroline Copithorne, Vice President, Morgan Stanley Equity Research

Speakers:

Gary Firestein, Head, Rhematology, UCSD; Paul Grint, Senior Director, Schering Plough; Sol Barer, COO, Celgene; Alan Lewis, President, Signal Pharmaceuticals

Understanding Biotechnology

This session is a training course for professionals with little or no training in biology. It will cover the basics of molecular biology, such as the structure and replication of DNA as well as protein composition and function. The function of enzymes and the importance of mutations in disease will be detailed. Subcloning, PCR, DNA sequencing and genetic mapping will be explained. A discussion of the Human Genome Project and its importance for all biology is fol-lowed by explanations of DNA array technologies, especial-ly as they relate to expression analysis, and participants will learn about the procesess of drug discovery, testing, trials and approval. Functional genomics and systems biology are examined, with an explanation of cloning technologies and stem cells capping off the seminar.

Chair: Laurie Hassell, President, ISTR, Inc.

Speakers:

Roger Bumgarner, Research Faculty, University of Washington Susan Mockus, Editor, Human Databases, Proteome, Inc.

Apoptosis-Based Therapies

Defects in apoptosis are estimated to directly or indirectly contribute to the pathogenesis of nearly 70 percent of all human illnesses, for which adequate therapies are currently lacking. Recent insights into cell death mechanisms are revealing strategies for development of new pharmaceuticals and other types of therapeutic strategies for combating defective apoptosis regulation during disease.

Co-Chairs: John Reed, Scientific Director, The Burnham Institute; Stuart Lipton, The Burnham Institute

Speakers:

John Reed, Scientific Director, The Burnham Institute; Kevin Tomaselli, Vice President, Discovery Research, Idun Pharmaceuticals; Avi Ashkenazi, Staff Scientist, Genentech, Inc.; Dale Bredesen, President and CEO, The Buck Institute for Age Research

Attacking Tumor Vasculature-A Cure for Cancer?

Therapies that inhibit the growth of new blood vessels - so-called angiogenesis inhibitors - offer considerable promise as anticancer agents. Recent insights into the heterogeneity of tumor vasculature and dissection of the complex network of mechanisms that controls tumor angiogenesis have revealed novel targets for development of therapeutic strategies for cancer treatment.

Chair: Kristiina Vuori, Assistant Professor, The Burnham Institute

Speakers:

Kristiina Vuori, Assistant Professor, The Burnham Institute; David Cheresh, Member, The Scripps Research Institute; Judith Varner, Associate Professor, UC San Diego; Brian Elicieri, Associate Member, The Scripps Research Institute; Douglas Hanahan, Associate Professor, UC San Francisco; Erkki Ruoslahti, Professor, President and CEO, The Burnham Institute

Partnering & Networking Opportunities.

The Technology Partnering Forum

Monday, June 25 - Wednesday, June 27, 2001

The Technology Partnering Forum will be a novel forum for companies, universities, nonprofits, scientists and other individuals to showcase their technologies available for licensing or commercialization, as well as to network with those interested in the same area of research and develop-ment. In contrast to previous years, where institutes and individuals discussed their technologies in 15-minute lecture presentations, this year's Technology Partnering exhibit will allow multiple institutes and individuals, from all over the world, to display their technologies for three hours in a topic-oriented poster presentation. Two poster sessions will be held each day of the three-day event, one in the morning and one in the afternoon, for a total of six sessions. In addition, because of the increasing interest in start-ups, there will be opportunities for scientists not only to present their inventions, but also to discuss and network with those involved in developing start-ups, including investors, law firms and development companies. By organizing the theme of each session to run in conjunction with the other events at BIO 2001, we expect the Technology Partnering exhibit to be one of the biggest draws of BIO 2001, where science and business can come together.

How can a research institution or early-stage biotechnology company apply to present in the Technology Partnering Forum?

Institutions and companies may apply for a three-hour table top display. Applications will be accepted on BIO's Web Site, www.bio.org , January 15-March 15, 2001.

What topic areas are appropriate for the Technology Partnering Forum?

We will be looking for submissions to showcase available technologies in the following areas:

• Cancer

• Cardiovascular - Autoimmune, Inflammation, Infectious Diseases

• Agriculture/BIO Production

• Devices/Delivery/Diagnostic

• Bioinformatics

• Central Nervous System/Neurology

Partnering & Investor Forum

Monday, June 25-Wednesday, June 27, 2001

BIO 2001 will again feature the Partnering & Investor Forum. This Forum provides participating biotechnology companies with opportunities to increase their exposure to both potential corporate partners and investors. Likewise, participation in this program gives potential corporate partners and investors an unparalleled opportunity to learn about a wide variety of biotechnology companies in one place, at one time. The Forum will span three days and include two presentation tracks as well as an expanded partnering forum.

What's new about the BIO 2001 Partnering & Investor Forum?

More than 120 companies will be organized by therapeutic area or platform technology to make it easier and more effi-cient for potential partners or investors to learn about the companies and technologies they are most interested in. In addition, the Partnering Forum will be themed in coordi-nation with the company presentations to make it easier for licensing executives with a particular focus to participate in this program and meet companies of most interest.

How can biotechnology companies apply to present in the Investor Forum?

Biotechnology companies may apply for a presentation slot at BIO's Business Development Web site: www.InvestInBio.com . Applications will be accepted from January 15 to March 15, 2001.

How can biotechnology companies participate in the Partnering Forum?

Please visit BIO's Business Development Web site: www.InvestInBio.com  for more information. As in the past, we plan to schedule half-hour meetings with the licensing or business development executives of participating pharmaceutical and large-cap biotechnology companies.

New-International Brunch Sunday Morning, June 24, 2001

International delegates are invited to the San Diego Convention Center on Sunday morning to complete registration and to pick up their meeting credentials. A networking brunch will allow international delegates to not only meet each other but to visit table top displays staffed by major research institutes of San Diego, such as The Salk Institute, the Scripps Research Institute and The Burnham Institute. Each country delegation will also be asked to staff a table to facilitate deal-making. A sit-down brunch will feature a keynote address pertinent to all members of the global biotechnology community.

Other BIO Programs

BIOParks, Saturday, June 23

A unique event to focus on how universities seek collaboration with industry, how parks are being built and what lies ahead for the industry. Learn how institutions like University of California-San Diego are creating unique partnerships to become leaders in this booming industry. Registration for BIOPARKS is not included in BIO 2001 registration. For more information, contact AURRP at (202) 828-4167.

Council of Biotechnology Centers, Monday, June 25

The Council of Biotechnology Centers (CBC) is a group comprised of varied institutional, research, and development agencies working for the scientific and economic advance-ment of biotechnology. The CBC Program at BIO 2001 will highlight key issues of importance to running and operating biotechnology centers. On Sunday, June 24, the CBC will host two ninety-minute sessions, "Fostering Entrepreneurship in Europe and the United States" and "Operations of Centers: Setting up and Managing Boards." A third session will be held Monday, June 25 in the BIO 2001 program Management Track. This session is titled "Best Practices in Workforce Development."

Procurement and Supply Chain Management Workshop Monday, June 25

Various sessions throughout the day to help the finance and purchasing professional learn how to procure products and services more efficiently to lower the cost of doing business. Current issues in procurement, such as B2B e-commerce, will be presented. This session is free to biotech profession-als and will include lunch and a complimentary pass to the exhibit hall for certain times during the day.

Teachers Program, Saturday, June 23 - Monday, June 25

Three days of programming, including lectures, tours, work-shops and hands-on experience for 100 teachers from mid-dle school, high school and community colleges. This pro-gram will build on two previous Teacher Professional Development Programs. Participants must complete an application process. Look for more information in future programs.

HealthFest, Sunday, June 24

New for BIO 2001! Featuring educational pavilions staffed by patient advocacy groups, research institutions, biomedical companies and medical delivery institutions. The San Diego community will have the opportunity to learn about local resources, health and social supports and biotech products that are currently available as well as those in the pipeline. Attendees may participate in hands-on activities and partake in a day of food and entertainment in a family-oriented environment. Admission is free and open to the public.

Career Fair, Sunday, June 24

Industry's largest career fair! Expecting over 75 companies conducting thousands of on-site interviews. The BIO 2001 Career Fair seeks to create opportunities for high-quality connections between candidates and biotech employers, and to generate excitement for biotech careers and industry employers who are actively recruiting. For a fee, companies can participate in the Career Fair by purchasing a booth or they can participate by posting avail-able positions, and having 'rèsumes' faxed directly to them from candidates. Interviewing will also take place on-site. Contact Ellen Fernandes at efernandes@bio.org  for more information. Become a Career Fair co-sponsor today! See page 14 or contact BIO for more information.

Breakfast Plenary Sessions, Monday, June 25 - Wednesday, June 27

In addition to our traditional luncheon programs, BIO 2001 will now feature spectacular breakfast plenary sessions. Don't sleep in or you'll miss the excitement! Keep checking our Web site for updates on speakers.

If you have come to this page from an outside location click here to get back to mindfully.org